Therapeutic uses of a C-RAF inhibitor

Patent metadata

Field	Value
Publication number	US-10973829-B2
Application number	US-201716332120-A
Country	US
Kind code	B2
Filing date	Sep 18, 2017
Priority date	Sep 19, 2016
Publication date	Apr 13, 2021
Grant date	Apr 13, 2021

Abstract

The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.

First claim

What is claimed:

1. A pharmaceutical combination comprising
(i) a CRAF inhibitor which is Compound A,

or a pharmaceutically acceptable salt thereof;
and
(ii) an ERK inhibitor which is Compound B,

or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical combination according to claim 1 , wherein the CRAF inhibitor, or a pharmaceutically acceptable salt thereof, and the ERK inhibitor, or a pharmaceutically acceptable salt thereof, are administered separately, simultaneously or sequentially.

3. A pharmaceutical composition comprising the pharmaceutical combination according to claim 1 and at least one pharmaceutically acceptable carrier.

4. A method for treating a proliferative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination according to claim 1 , wherein the proliferative disease is selected from KRAS-mutant NSCLC (non-small cell lung cancer), KRAS-mutant pancreatic cancer, and KRAS-mutant colorectal cancer (CRC).

5. The method according to claim 4 wherein the cancer expresses at least one mutation selected from the group consisting of RAS mutations G12S, Q61H, Q61K, G12D, G12C, G13D, G12V, and G12R.

6. The method according to claim 4 , wherein the c-RAF kinase inhibitor, or a pharmaceutically acceptable salt thereof, is administered at a daily dose of about 100 mg, or about 150 mg, or about 200 mg, or about 250 mg.

7. The method according to claim 4 , wherein the ERK inhibitor, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 50 mg per day, or about 75 mg per day, or about 100 mg per day.

8. The method according to claim 4 , wherein Compound A is administered at a daily dose of 100 mg and Compound B is administered at a daily dose of 100 mg.

9. The method according to claim 4 , wherein Compound A is administered at a daily dose of 200 mg and Compound B is administered at a daily dose of 100 mg.

10. A combined preparation comprising (a) one or more dosage units of a CRAF inhibitor according to claim 1 , or a pharmaceutically acceptable salt thereof, and (b) one or more dosage units of an ERK inhibitor according to claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

11. A method of treating a proliferative disorder selected from KRAS-mutant NSCLC, KRAS-mutant pancreatic cancer, and KRAS-mutant colorectal cancer, by administering to a patient in need thereof, a CRAF inhibitor which is Compound A,

or a pharmaceutically acceptable salt thereof, in combination with an ERK inhibitor which is compound B,

or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 wherein the proliferative disease is a cancer that expresses at least one mutation selected from the group consisting of RAS mutations G12S, Q61H, Q61K, G12D, G12C, G13D, G12V, and G12R.

Assignees

• Novartis Ag

Inventors

• Caponigro Giordano
• Cooke Vesselina
• Meyer Matthew John
• Stuart Darrin

Classifications

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/5377 Primary

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title

• A61K31/505

  Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title

• A61K31/4965

  Non-condensed pyrazines · CPC title